--- title: "Bioxytran, Inc. | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286598224.md" datetime: "2026-05-15T17:37:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286598224.md) - [en](https://longbridge.com/en/news/286598224.md) - [zh-HK](https://longbridge.com/zh-HK/news/286598224.md) --- # Bioxytran, Inc. | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.02. EBIT: As of FY2026 Q1, the actual value is USD -1.872 M. Bioxytran, Inc. operates as a single segment and has not yet generated significant revenues from its pharmaceutical products, remaining in the research and development phase as of March 31, 2026. #### Operational Metrics - **Net Loss**: The company reported a net loss of - $2,068,989 for the three months ended March 31, 2026, an increase from - $1,353,635 for the same period in 2025, primarily due to a $1,278,600 bonus award to the CEO in January 2026. - **Total Operating Expenses**: Total operating expenses for the three months ended March 31, 2026, were $1,933,053, up from $515,142 in the prior year period. - **Research and Development (R&D) Expenses**: R&D expenses decreased to $225,479 for the three months ended March 31, 2026, compared to $349,500 for the same period in 2025. This includes $3,000 for process development, $225 for product development, $216,254 for regulatory, $0 for clinical trials, and $6,000 for project management. - **General and Administrative (G&A) Expenses**: G&A expenses significantly increased to $1,707,574 for the three months ended March 31, 2026, from $165,642 in the corresponding 2025 period. Key components include $262,567 for payroll and related expenses, $51,588 for legal, accounting, and other professional services, $36,000 for marketing expense, $67,404 for miscellaneous G&A expenses, $1,278,600 for compensation expense to BoD and Management, and $11,415 for compensation expense to consultants. - **Other Expenses**: Total other expenses were $135,936 for the three months ended March 31, 2026, a decrease from $838,493 in the same period of 2025. This includes a change in fair value of derivative of $73,136, interest expense of $35,729, interest expense affiliate of $24,963, and amortization of Intellectual Property of $2,108. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $238,610 for the three months ended March 31, 2026, compared to - $167,323 for the same period in 2025. - **Net Cash Used in Investing Activities**: Net cash used in investing activities was - $9,227 for the three months ended March 31, 2026, primarily for filing a patent, compared to - $15 in 2025. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities totaled $200,970 for the three months ended March 31, 2026, including $145,701 from stock sales and $95,339 from warrant sales, partially offset by - $40,070 in short-term loans from affiliates. This compares to $166,532 provided by financing activities in 2025, primarily from affiliate loans. - **Cash, End of Period**: Cash on hand at March 31, 2026, was $463,047, a decrease from $509,914 at the beginning of the period. #### Unique Metrics - **Accumulated Deficit**: The accumulated deficit increased to - $23,113,235 at March 31, 2026, from - $21,044,246 at December 31, 2025. - **Net Working Capital**: Net working capital was - $4,547,075 at March 31, 2026, worsening from - $2,736,429 at December 31, 2025. - **Current Assets**: Total current assets were $463,047 at March 31, 2026, down from $513,465 at December 31, 2025. - **Current Liabilities**: Total current liabilities increased to $5,010,121 at March 31, 2026, from $3,249,894 at December 31, 2025. This includes accounts payable and accrued expenses of $1,065,504, accounts payable affiliates of $869,237, un-issued shares liability of $27,687, un-issued shares liability affiliates of $1,360,606, loan from affiliates of $355,598, other short-term loans of $50,000, derivative liability of $476,489, and convertible notes payable of $805,000. - **Convertible Notes Payable**: The principal amount of convertible notes payable remained at $805,000 at March 31, 2026, with accrued interest of $313,685. The 2021 Note has been in default since March 1, 2025, incurring an 18% default interest rate. - **Derivative Liability**: The derivative liability was $476,489 at March 31, 2026, compared to $403,353 at December 31, 2025. - **Stock-based compensation expense**: Stock-based compensation expense totaled $1,290,015 for the three months ended March 31, 2026, with $1,278,600 attributed to affiliates. #### Future Outlook and Strategy Bioxytran, Inc. anticipates needing to raise approximately $2-3 million in 2026 to fund operations and continue product development for the next 15 months. The company plans to pursue additional capital through private placements and/or public offerings of debt and/or equity securities. Without sufficient additional funding or strategic partnerships, Bioxytran, Inc. may be forced to curtail or cease operations. ### Related Stocks - [BIXT.US](https://longbridge.com/en/quote/BIXT.US.md) ## Related News & Research - [Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonist](https://longbridge.com/en/news/295525258.md) - [08:36 ETBCA IT, Inc. Named No. 1700 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America's Fastest-Growing Private Companies](https://longbridge.com/en/news/296229672.md) - [QDM International Inc. GAAP EPS of $0.36, revenue of $8.39M](https://longbridge.com/en/news/296145995.md) - [Elauwit Connection, Inc. Reschedules Second Quarter 2026 Results and Conference Call to August 18, 2026 | ELWT Stock News](https://longbridge.com/en/news/295850756.md) - [10:06 ETUnleashed Brands Ranks No. 4167 on 2026 Inc. 5000 for Second Consecutive Year](https://longbridge.com/en/news/295549072.md)